ITCI — Intra-Cellular Therapies Cashflow Statement
0.000.00%
Last trade - 00:00- $14.04bn
- $13.04bn
- $680.85m
- 62
- 13
- 87
- 54
Annual cashflow statement for Intra-Cellular Therapies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -227 | -284 | -256 | -140 | -74.7 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 23.7 | 30.4 | 43.5 | 44.5 | 55.1 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -27.5 | -6.35 | -58.1 | -29.6 | -54.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -230 | -260 | -270 | -124 | -73.2 |
| Capital Expenditures | -0.267 | -0.326 | -0.778 | -0.269 | -0.322 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -480 | 281 | -128 | 106 | -335 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -480 | 280 | -128 | 106 | -335 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 664 | 11.5 | 455 | 17.8 | 568 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -46.2 | 32.3 | 56.6 | -0.848 | 159 |